Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: This phase 3 trial compared the efficacy and safety of rivaroxaban, an oral direct inhibitor of factor Xa, with those of enoxaparin for extended thromboprophylaxis in patients undergoing total hip arthroplasty. METHODS: In this randomized, double-blind study, we assigned 4541 patients to receive either 10 mg of oral rivaroxaban once daily, beginning after surgery, or 40 mg of enoxaparin subcutaneously once daily, beginning the evening before surgery, plus a placebo tablet or injection. The primary efficacy outcome was the composite of deep-vein thrombosis (either symptomatic or detected by bilateral venography if the patient was asymptomatic), nonfatal pulmonary embolism, or death from any cause at 36 days (range, 30 to 42). The main secondary efficacy outcome was major venous thromboembolism (proximal deep-vein thrombosis, nonfatal pulmonary embolism, or death from venous thromboembolism). The primary safety outcome was major bleeding. RESULTS: A total of 3153 patients were included in the superiority analysis (after 1388 exclusions), and 4433 were included in the safety analysis (after 108 exclusions). The primary efficacy outcome occurred in 18 of 1595 patients (1.1%) in the rivaroxaban group and in 58 of 1558 patients (3.7%) in the enoxaparin group (absolute risk reduction, 2.6%; 95% confidence interval [CI], 1.5 to 3.7; P<0.001). Major venous thromboembolism occurred in 4 of 1686 patients (0.2%) in the rivaroxaban group and in 33 of 1678 patients (2.0%) in the enoxaparin group (absolute risk reduction, 1.7%; 95% CI, 1.0 to 2.5; P<0.001). Major bleeding occurred in 6 of 2209 patients (0.3%) in the rivaroxaban group and in 2 of 2224 patients (0.1%) in the enoxaparin group (P=0.18). CONCLUSIONS: A once-daily, 10-mg oral dose of rivaroxaban was significantly more effective for extended thromboprophylaxis than a once-daily, 40-mg subcutaneous dose of enoxaparin in patients undergoing elective total hip arthroplasty. The two drugs had similar safety profiles. (ClinicalTrials.gov number, NCT00329628.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We identified 1 RCT 317 to inform this recommendation.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [317]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The investigation into the use of the lower doses of these 2 anticoagulants for secondary prevention was prompted by the desire to reduce the risk of bleeding, as well as the documented efficacy of the lower doses to prevent VTE after elective hip or knee arthroplasty. 317-321”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [317]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevention of Venous Thromboembolism
Geerts, W. H., Pineo, G. F., Heit, J. A., Bergqvist, D., Lassen, M. R., Colwell, C. W., & Ray, J. G. (2004) · Chest · doi:10.1378/chest.126.3_suppl.338s · Cited by 5,895
Self-citationThe Pharmacology and Management of the Vitamin K Antagonists
Ansell, J., Hirsh, J., Poller, L., Bussey, H., Jacobson, A., & Hylek, E. (2004) · Chest · doi:10.1378/chest.126.3_suppl.204s · Cited by 1,528
Eriksson, B. I., Dahl, O. E., Rosencher, N., Kurth, A. A., van Dijk, C. N., Frostick, S. P., Prins, M. H., Hettiarachchi, R., Hantel, S., Schnee, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61445-7 · Cited by 1,116
Self-citationRoentgen Diagnosis of Venous Thrombosis in the Leg
Rabinov, K. (1972) · Archives of Surgery · doi:10.1001/archsurg.1972.04180020014004 · Cited by 740
Turpie, A. G. G. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.16.1833 · Cited by 736
KUBITZA, D., BECKA, M., VOITH, B., ZUEHLSDORF, M., & WENSING, G. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.06.011 · Cited by 649
Kubitza, D., Becka, M., Wensing, G., Voith, B., & Zuehlsdorf, M. (2005) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-005-0043-5 · Cited by 640
Eriksson, B. I., Bauer, K. A., Lassen, M. R., & Turpie, A. G. G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011100 · Cited by 631
Self-citationRosencher, N., Kerkkamp, H. E. M., Macheras, G., Munuera, L. M., Menichella, G., Barton, D. M., Cremers, S., Abraham, I. L., & Investigation, F. T. O. (2003) · Transfusion · doi:10.1046/j.1537-2995.2003.00348.x · Cited by 603
Eikelboom, J. W., Quinlan, D. J., & Douketis, J. D. (2001) · The Lancet · doi:10.1016/s0140-6736(00)05249-1 · Cited by 513
Research works printed but not linked: 1
- 10.1016/s0140-6736(07)61445-7 · DOI · Paper page
Cited by
Items 601–700 of 1,000
Appropriateness of Dabigatran and Rivaroxaban Prescribing for Hospital Inpatients
Chowdhry, U., Jacques, A., Karovitch, A. J., Giguère, P., & Nguyen, M.-L. (2016) · The Canadian Journal of Hospital Pharmacy · doi:10.4212/cjhp.v69i3.1555 · Cited by 17
Godiér, A., Lasne, D., Pernod, G., Blais, N., Bonhomme, F., Bounes, F. V., Bourguignon, A., Cohen, A. A., de Maistre, E., Fontana, P., et al. (2024) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2024.101446 · Cited by 18
Drabik, A., Hillgruber, C., & Goerge, T. (2014) · JMIR Research Protocols · doi:10.2196/resprot.3640 · Cited by 14
Contemporary management of pulmonary embolism: the answers to ten questions
Bounameaux, H. M. (2010) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2010.02254.x · Cited by 17
Gill, S. K., Pearce, A. R., Everington, T., & Rossiter, N. D. (2019) · The Surgeon · doi:10.1016/j.surge.2019.11.002 · Cited by 15
Watts, P. J., Kopstein, M., Harkness, W., Cornett, B., Dziadkowiec, O., Hicks, M., Hassan, S., & Scherbak, D. (2021) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2599 · Cited by 15
Alternatives to Warfarin-The Next Generation of Anticoagulants
Kanagasabapathy, P., Chowdary, P., & Gatt, A. (2010) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2010.00197.x · Cited by 14
“2% in the three studies) [34–36].”
Pow, R. E., & Vale, P. R. (2015) · Internal Medicine Journal · doi:10.1111/imj.12675 · Cited by 15
“Pooled analysis of data from the RECORD trials [32-35] revealed a 0.”
MethodResultVerheugt, F. W. A. (2010) · Netherlands Heart Journal · doi:10.1007/bf03091782 · Cited by 17
Agnelli, G., Gallus, A. S., Lassen, M. R., Prins, M. H., Renfurm, R. W., Kashiwa, M., Turpie, A. G. G., & Eriksson, B. I. (2014) · Thrombosis and Haemostasis · doi:10.1160/th13-04-0296 · Cited by 14
“Transient elevations of liver transaminases and/or bilirubin have been previously reported in clinical studies with enoxaparin and other direct FXa inhibitors, including dabigatran and rivaroxaban (11, 17, 22, 23, 54, 55).”
BackgroundResultInfluentialSelf-citationTun, N. M., & Oo, T. H. (2013) · Thrombosis · doi:10.1155/2013/183616 · Cited by 16
“The RECORD1 study compared rivaroxaban (10mg once daily for 35 days) to enoxaparin (40mg once daily for 35 days) [47].”
BackgroundFriedman, R. J., Sengupta, N., & Lees, M. (2011) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/erp.11.15 · Cited by 15
Self-citationA review of the two major regulatory pathways for non-proprietary low-molecular-weight heparins
Ofosu, F. A. (2012) · Thrombosis and Haemostasis · doi:10.1160/th11-06-0409 · Cited by 16
Dall, C. P., Shaw, N. M., Egan, J. M., Carvalho, F. L. F., Galloway, L. A., Krasnow, R. E., & Stamatakis, L. (2020) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2020.05.030 · Cited by 14
Practical management of new oral anticoagulants after total hip or total knee arthroplasty
Klauser, W., & Dütsch, M. (2013) · MUSCULOSKELETAL SURGERY · doi:10.1007/s12306-013-0306-8 · Cited by 15
“RECORD1 and RECORD3 were head-to-head drug regimen comparisons, whereas RECORD2 compared extended-duration rivaroxaban with short-duration enoxaparin followed by placebo [16, 35, 42].”
BackgroundNovel oral anticoagulants to prevent stroke in atrial fibrillation
Verheugt, F. W. A. (2010) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2009.235 · Cited by 15
New options in anticoagulation for the prevention of venous thromboembolism and stroke.
Clayville, L. R., Anderson, K. V., Sa, M., & Onge, E. S. (2011) · PubMed Central · Cited by 16
Danhong huayu koufuye prevents deep vein thrombosis through anti-inflammation in rats
Zhang, Z., Hu, L., Chen, W., Zhou, C., Gui, G., & Lin, B. (2015) · Journal of Surgical Research · doi:10.1016/j.jss.2015.11.008 · Cited by 14
“[19] Eriksson BI, Borris LC, Friedman RJ, et al.”
BackgroundTeng, Y., Ma, J., Ma, X., Wang, Y., Lu, B., & Guo, C. (2017) · Medicine · doi:10.1097/md.0000000000006763 · Cited by 17
“Approximately half of the patients who underwent total hip or TKA received more than 2U of blood transfusion after surgery.([1,2]) Allogeneic blood transfusion after TJA is very common, but allogeneic blood transfusion is not without risk.”
BackgroundZheng, S. S., Luo, S., Mei, Y., Guo, J., Tong, L.-J., Zhang, Q., & Ye, X.-Y. (2018) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-018-0504-8 · Cited by 14
The Utility of Rivaroxaban as Primary Venous Thromboprophylaxis in an Adult Trauma Population
Kingdon, L. K., Miller, E. M., & Savage, S. A. (2019) · Journal of Surgical Research · doi:10.1016/j.jss.2019.06.079 · Cited by 18
Reinecke, I., Solms, A., Willmann, S., Spiro, T. E., Peters, G. R., Weitz, J. I., Mueck, W., Garmann, D., Schmidt, S., Zhang, L., et al. (2020) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-020-02078-8 · Cited by 14
Implementing the new oral anticoagulants into the hospital formulary
Palladino, M. A., Thomson, L. J., Swift, B. G., & Merli, G. J. (2012) · American Journal of Hematology · doi:10.1002/ajh.23208 · Cited by 13
SBA 2020: Regional anesthesia guideline for using anticoagulants update
Fonseca, N. M., Pontes, J. P. J., Perez, M. V., Alves, R. R., & Fonseca, G. G. (2020) · Brazilian Journal of Anesthesiology (English Edition) · doi:10.1016/j.bjane.2020.04.018 · Cited by 20
Management of Bleeding Complications in the Anticoagulated Patient
Bhagirath, V. C., O’Malley, L., & Crowther, M. A. (2011) · Seminars in Hematology · doi:10.1053/j.seminhematol.2011.08.008 · Cited by 14
New oral anticoagulants for thromboprophylaxis in patients having hip or knee arthroplasty
Eikelboom, J. W., & Weitz, J. I. (2011) · BMJ · doi:10.1136/bmj.c7270 · Cited by 14
Mahan, C. E., & Spyropoulos, A. C. (2012) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp120236 · Cited by 14
Edoxaban in cardiovascular disease management: Review
Srinivasan, S., Ajmal, M., Pecci, C., & Lassar, T. A. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15026 · Cited by 13
Chapelle, C., Bertoletti, L., Lega, J., Cucherat, M., Zufferey, P. J., Darmon, J., Mismetti, P., Laporte, S., & the META-EMBOL Group (2014) · Thrombosis and Haemostasis · doi:10.1160/th14-01-0064 · Cited by 15
Rogers, B. A., Phillips, S., Foote, J., & Drabu, K. J. (2010) · Annals of The Royal College of Surgeons of England · doi:10.1308/003588410x12699663904952 · Cited by 14
Wolzt, M., Gouya, G., Kapiotis, S., Becka, M., Mueck, W., & Kubitza, D. (2013) · Thrombosis Research · doi:10.1016/j.thromres.2013.05.019 · Cited by 13
“Rivaroxaban has demonstrated consistent efficacy and reassuring safety in large-scale phase III clinical trials across several indications [13–20].”
BackgroundRivaroxaban for Thromboprophylaxis in Patients Undergoing Major Orthopedic Surgery
Melillo, S. N., Scanlon, J. V., Exter, B. P., Steinberg, M., & Jarvis, C. I. (2010) · Annals of Pharmacotherapy · doi:10.1345/aph.1m681 · Cited by 13
NEW ANTICOAGULANTS AS THROMBOPROPHYLAXIS AFTER TOTAL HIP OR KNEE REPLACEMENT
Hamidi, V., Ringerike, T., Hagen, G., Reikvam, Å., & Klemp, M. (2013) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462313000251 · Cited by 13
When patients on target-specific oral anticoagulants need surgery
Anderson, M., Hassell, K. L., Trujillo, T. C., & Wolfe, B. (2014) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.81a.13168 · Cited by 13
New oral anticoagulants – a review
Ghanima, W., Atar, D., & Sandset, P. M. (2013) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.12.1111 · Cited by 18
“Rivaroxaban The clinical trials to investigate post-operative thromboprophylaxis with rivaroxaban after total hip or knee replacement surgery covered a total of 12 500 patients (3, 5, 12, 13).”
BackgroundBreakthroughs in Anticoagulation: Advent of the Oral Direct Factor Xa Inhibitors
Augoustides, J. G. (2012) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2012.03.029 · Cited by 14
Huang, M., Wei, R., Li, Q., Yang, X., Cao, C.-M., Su, T.-Y., Wang, N., Wang, R., & Chen, X. (2015) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1247-x · Cited by 13
Yoshida, R. D. A., Yoshida, W. B., & Rollo, H. A. (2011) · Jornal Vascular Brasileiro · doi:10.1590/s1677-54492011000200009 · Cited by 21
The Quest for New Anticoagulants: From Clinical Development to Clinical Practice
Apostolakis, S. Z., Lip, G. Y. H., Lane, D. A., & Shantsila, E. (2010) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2010.00160.x · Cited by 16
Novos anticoagulantes em cuidados intensivos
Flato, U. A. P., Buhatem, T., Merluzzi, T., & Bianco, A. C. (2011) · Revista Brasileira de Terapia Intensiva · doi:10.1590/s0103-507x2011000100012 · Cited by 15
Haas, S. K., Holberg, G., Kreutz, R. H., Lassen, M. R., Mantovani, L. G., Haupt, V., Vogtländer, K., & Turpie, A. G. G. (2016) · Vascular Health and Risk Management · doi:10.2147/vhrm.s100293 · Cited by 14
“2–6 The effectiveness and safety of rivaroxaban in unselected patients in routine clinical practice were confirmed in XAMOS, a noninterventional, Phase IV study, which demonstrated that rivaroxaban was associated with a lower incidence of symptomatic thromboembolic events compared with…”
Self-citationRivaroxaban for Thromboprophylaxis After Nonelective Orthopedic Trauma Surgery in Switzerland
Hoffmeyer, P. J., Simmen, H., Jakob, M., Sommer, C., Platz, A., Ilchmann, T., Grossen, E., Ryf, C., Christofilopoulos, P., Schueler, M., et al. (2016) · Orthopedics · doi:10.3928/01477447-20161116-05 · Cited by 16
“Time to discharge after mobilization, median (range), d 9 (3-27) 9 (3-38) 4 (0-18) 5 (0-41)”
BackgroundInfluentialHelin, T., Virtanen, L., Manninen, M. J., Leskinen, J., Leppilahti, J. I., Joutsi‐Korhonen, L., & Lassila, R. (2017) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-017-1492-2 · Cited by 13
“The dosages for this indication are 2.5 mg BID for apixaban and 10 mg OD for rivaroxaban, and they have been reported to be superior to enoxaparin for thromboprophylaxis after THA [1, 2].”
BackgroundInfluentialRao, B. B., Kalayarasan, R., Kate, V., & Ananthakrishnan, N. (2012) · ISRN Vascular Medicine · doi:10.5402/2012/783214 · Cited by 13
Rosencher, N., Bellamy, L., & Arnaout, L. (2009) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2009.02.007 · Cited by 13
“[9] Eriksson BI, Borris LC, Friedman RJ, et al.”
BackgroundGong, X., Tang, S., Li, J., Zhang, X., Tian, X., & Ma, S. (2017) · PLoS ONE · doi:10.1371/journal.pone.0186449 · Cited by 12
Anticoagulation strategies for venous thromboembolism: moving towards a personalised approach
Cohen, A. T., & Black, S. A. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-12-1028 · Cited by 15
Pharmacology of Anticoagulants
Loke, C., Ali, S. S., & Johari, V. P. (2012) · Disease-a-Month · doi:10.1016/j.disamonth.2012.04.005 · Cited by 12
Changing anticoagulant paradigms for atrial fibrillation: dabigatran, apixaban and rivaroxaban
Giorgi, M. A., Arazi, H. C., González, C. D., & Girolamo, G. D. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.528754 · Cited by 13
Venous thromboembolism: identifying patients at risk and establishing prophylaxis
Shirvanian, S., & Tapson, V. F. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1098599 · Cited by 14
Raymundo, S. R. D. O., Lobo, S. M., Hussain, K. M. K., Hussein, K. G., & Secches, I. T. (2019) · Jornal Vascular Brasileiro · doi:10.1590/1677-5449.002118 · Cited by 42
Cheallaigh, S. N., Fleming, A., Dahly, D. L., Kehoe, E., O’Byrne, J., McGrath, B., O’Connell, C., & Sahm, L. J. (2020) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-020-01032-1 · Cited by 14
SBA 2020: Atualização na diretriz da anestesia regional em uso de anticoagulantes
Fonseca, N. M., Pontes, J. P. J., Perez, M. V., Alves, R. R., & Fonseca, G. G. (2020) · Brazilian Journal of Anesthesiology · doi:10.1016/j.bjan.2020.02.006 · Cited by 13
Ikesaka, R., Kaur, B., Crowther, M. A., & Rajasekhar, A. (2022) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-022-02689-3 · Cited by 12
Agarwal, A. R., Ahmed, A. F., Stadecker, M. J., Miller, A. S., Best, M. J., & Srikumaran, U. (2023) · Journal of the American Academy of Orthopaedic Surgeons · doi:10.5435/jaaos-d-22-00825 · Cited by 12
Antagonisation des héparines et des nouveaux anticoagulants
Kortchinsky, T., Vigué, B., & Samama, C. M. (2012) · Annales Françaises d Anesthésie et de Réanimation · doi:10.1016/j.annfar.2012.10.034 · Cited by 15
Özler, T., Uluçay, Ç., Önal, A., & Altıntaş, F. (2015) · Acta Orthopaedica et Traumatologica Turcica · doi:10.3944/aott.2015.14.0219 · Cited by 12
Wang, C., Liu, Q., Sun, L., & Dai, G. (2019) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000000839 · Cited by 12
Wæver, D., Lewis, D. P., Saksø, H., Borris, L. C., Tarrant, S. M., & Thorninger, R. (2020) · Journal of Orthopaedic Trauma · doi:10.1097/bot.0000000000001962 · Cited by 16
Self-citationVenous thromboembolism prophylaxis in high-risk orthopedic and cancer surgery
D’Astous, J., Liederman, Z., & Douketis, J. D. (2021) · Postgraduate Medicine · doi:10.1080/00325481.2021.1891751 · Cited by 15
Efficacy and Safety of Thromboprophylaxis Post-Orthopedic Surgery
Alsheikh, K., Hilabi, A. S., Aleid, A., Alharbi, K. G., Alangari, H. S., Alkhamis, M., Alzahrani, F., & Almadani, W. H. (2021) · Cureus · doi:10.7759/cureus.19691 · Cited by 16
“DOI 10.7759/cureus.19691 4 of 12 2009, Multinational [26] TKA randomized, double-blind phase 3 trial mg o.d., 6–8 hours postoperatively) mg b.i.d., 12 hours preoperatively) to enoxaparin; there was no statistically different bleeding risk between the two arms surgical site bleeding was excluded from major bleeding Eri…”
BackgroundInfluentialNederpelt, C. J., Naar, L., Meier, K., Wijck, S. F. M. V., Krijnen, P., Velmahos, G. C., Kaafarani, H. M. A., Rosenthal, M. G., & Schipper, I. B. (2022) · European Journal of Trauma and Emergency Surgery · doi:10.1007/s00068-022-01938-7 · Cited by 12
Dhillon, N. K., Haut, E. R., Price, M. A., Costantini, T. W., Teichman, A. L., Cotton, B. A., & Ley, E. J. (2022) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0000000000003853 · Cited by 12
“Eriksson et al.33 conducted a phase 3 trial (Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thrombosis and Pulmonary Embolism 1) comparing rivaroxaban 10 mg once daily to enoxaparin 40 mg once daily in patients undergoing total hip arthroplasty.”
MethodHirsh, J., Ginsberg, J. S., Chan, N., Guyatt, G. H., & Eikelboom, J. W. (2014) · Thrombosis and Haemostasis · doi:10.1160/th13-07-0562 · Cited by 14
“Despite differences in the incidence of asymptomatic venographic thrombosis in contemporary clinical trials in elective major orthopaedic surgery comparing newer anticoagulants with enoxaparin (18-28), the post-operative mortality, assessed at the time of venography is very low and similar among groups (▶ Table 2).”
BackgroundBorris, L. C. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560902835513 · Cited by 13
“In another recent study, the same dosages of dabigatran etexilate did not establish non-inferiority for the primary efficacy outcome (total VTE) compared with enoxaparin 30 mg twice daily after TKA [31].”
BackgroundInfluentialSelf-citationRecent developments in the use of oral anticoagulants
Lassen, M. R. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903042325 · Cited by 13
“for 31 – 39 days) in patients undergoing THR [44].”
BackgroundPharmacological prevention of venous thromboembolism in orthopaedic surgery
Prisco, D., Cenci, C., Silvestri, E., Emmi, G., & Ciucciarelli, L. (2014) · Clinical cases in mineral and bone metabolism · doi:10.11138/ccmbm/2014.11.3.192 · Cited by 15
“Considering the available studies in which these drugs were compared with the preoperative administration of LMWH (9-14) it appears that: • Apixaban showed greater safety than LMWH, with a similar efficacy; • Dabigatran showed non-inferiority versus LMWH in terms of both efficacy and safety; • Rivaroxaban demonstrated…”
BackgroundInfluentialPilge, H., Fröbel, J., Prodinger, P. M., Mrotzek, S. J., Fischer, J., Zilkens, C., Bittersohl, B., & Krauspe, R. (2016) · Bone and Joint Research · doi:10.1302/2046-3758.53.2000595 · Cited by 12
Effects of novel oral anticoagulants on left atrial and left atrial appendage thrombi: an appraisal
Marsico, F., Cecere, M., Parente, A., Paolillo, S., Martino, F. D., Dellegrottaglie, S., Trimarco, B., & Filardi, P. P. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-016-1421-9 · Cited by 14
Arnold, W. V., Bari, A. K., Buttaro, M. A., Huang, R. C., Mirez, J. P., Neira, I., Poojary, A. A., Purtill, J. J., Quevedo, M. S., Ricaurte, J. C. G., et al. (2018) · The Journal of Arthroplasty · doi:10.1016/j.arth.2018.09.067 · Cited by 12
Krauss, E. S., Dengler, N., Simonson, B. G., Altner, K., Daly, M., Segal, A., & Cronin, M. (2018) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0038-1676319 · Cited by 12
Novel Oral Anticoagulants: New Challenges for Anesthesiologists in Bleeding Patients
Spahn, D. R., & Korte, W. C. (2011) · Anesthesiology · doi:10.1097/aln.0b013e318238c070 · Cited by 14
The risk of infection with new oral anticoagulants: A meta-analysis
Caldeira, D., Costa, J. N., Pinto, F. J., & Ferreira, J. J. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.12.248 · Cited by 12
Wang, S. V., Russo, M., Glynn, R. J., Bradley, M. C., He, J., Concato, J., & Schneeweiss, S. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3621 · Cited by 11
Ogilvie, J. W., Khan, M. T., Hayakawa, E., Parker, J., & Luchtefeld, M. A. (2023) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000003107 · Cited by 11
SBA Recommendations for regional anesthesia safety in patients taking anticoagulants
Fonseca, N. M., de Anestesiologia, S. B., Alves, R. R., & Pontes, J. P. J. (2013) · Brazilian Journal of Anesthesiology (English Edition) · doi:10.1016/j.bjane.2013.04.010 · Cited by 19
Lassen, M. R. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03328.x · Cited by 11
Morris, T. A. (2010) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2010.06.006 · Cited by 12
Oral and parenteral anticoagulants: New kids on the block
Aditya, S. (2012) · Journal of Postgraduate Medicine · doi:10.4103/0022-3859.105448 · Cited by 12
Nafee, T., Aslam, A., Chi, G., Pahlavani, S., Nimri, D., Kuchkuntla, A. R., Talib, U., Michalak, N., Daaboul, Y., Korjian, S., et al. (2017) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2017.1305889 · Cited by 11
Venous Thromboembolism Prophylaxis After Total Joint Arthroplasty
Flierl, M. A., Messina, M. J., Mitchell, J. J., Hogan, C. A., & D'Ambrosia, R. D. (2015) · Orthopedics · doi:10.3928/01477447-20150402-06 · Cited by 11
Liang, J. Q., Bergqvist, D., Yusen, R. D., & Hull, R. D. (2014) · Thrombosis and Haemostasis · doi:10.1160/th13-08-0654 · Cited by 11
“Eligible studies included phase II and phase III trials that evaluated the prophylactic regimens of fondaparinux (four phase III studies [28–32]), dabigatran (four phase III studies [7–10]), rivaroxaban (one phase II study [2] and three phase III studies [3, 5, 6]), and apixaban (three phase III studies [11–13]) and c…”
BackgroundMills, R. M., Berkowitz, R. D., Damaraju, C. V., Jennings, L. K., & Wildgoose, P. (2012) · Thrombosis Research · doi:10.1016/j.thromres.2012.07.014 · Cited by 11
“These double-blind, multicentre, multinational trials were conducted in more than 12,500 patients worldwide and demonstrated that rivaroxaban had superior efficacy to the low molecular weight heparin (LMWH) enoxaparin, with similar safety [7–10].”
BackgroundBeyer‐Westendorf, J., Cohen, A. T., & Monréal, M. (2015) · European Heart Journal Supplements · doi:10.1093/eurheartj/suv034 · Cited by 13
Pathak, R., Giri, S., Karmacharya, P., Aryal, M. R., Poudel, D. R., Ghimire, S., Jehangir, A., Shaikh, B. F., Rettew, A., & Donato, A. A. (2015) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000000369 · Cited by 12
Gómez, D., Razmjou, H., Donovan, A., Bansal, V., Gollish, J. D., & Murnaghan, J. J. (2016) · The Journal of Arthroplasty · doi:10.1016/j.arth.2016.09.021 · Cited by 12
García-Escobar, I., Brozos-Vázquez, E., Abad, D. G., Martínez-Marín, V., Pachón, V., & Martín, A. J. M. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02506-4 · Cited by 13
Yu, J., Jin, Y., Chen, X., Fang, C., Zhang, Z., Chen, L., & Xu, G. (2023) · Molecular Biotechnology · doi:10.1007/s12033-023-00676-4 · Cited by 11
Kauffmann, S., Chabanne, R., Coste, A., Longeras, F., Sinegre, T., Schmidt, J., Samama, C. M., Constantin, J., & Lebreton, A. (2015) · A & A Case Reports · doi:10.1213/xaa.0000000000000143 · Cited by 11
Monitoring of direct anticoagulants
Lison, S., & Spannagl, M. (2011) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-011-0876-8 · Cited by 15
“[1, 3, 7, 11].”
BackgroundUnanswered Questions, Unmet Needs in Venous Thromboprophylaxis
Cushner, F. D., & Nett, M. P. (2009) · Orthopedics · doi:10.3928/01477447-20091103-50 · Cited by 11
Oral factor Xa inhibitors for thromboprophylaxis in major orthopedic surgery: a review
Imberti, D., Dall’Asta, C., & Giorgi‐Pierfranceschi, M. (2009) · Internal and Emergency Medicine · doi:10.1007/s11739-009-0293-9 · Cited by 12
“The RECORD studies show that the primary efficacy outcome (a composite of any DVT, non-fatal PE, or death from any cause up to 30‐42 days after surgery [ 28 , 29 ]o r within 13‐17 days after surgery [30, 31]) occurs in 1.1‐9.6% of the patients in the rivaroxaban group and in 3.7‐18.9% of the patients in the enoxaparin…”
BackgroundResultInfluentialArcelus, J. I., Domènech, P., Fernández-Capitan, M. D. C., Guijarro, R., Jiménez, D., Jiménez, S., Lozano, F. S., Monreal, M., Nieto, J. A., & Páramo, J. A. (2014) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029614561321 · Cited by 14
Loganathan, V., Hua, A. X., Patel, S. A., Gibbons, C. E. R., & Vizcaychipi, M. P. (2016) · Annals of The Royal College of Surgeons of England · doi:10.1308/rcsann.2016.0197 · Cited by 12
“Outpatient thromboprophylaxis Rivaroxaban start day – days median (IQR) 6 (1) 6 (4) 0.”
BackgroundTalukdar, A., Wang, S. K., Czosnowski, L. M., Mokraoui, N., Gupta, A., Fajardo, A. C., Dalsing, M. C., & Motaganahalli, R. L. (2017) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2017.02.052 · Cited by 11
Current status of rivaroxaban in elderly patients with pulmonary embolism (Review)
Song, Z., Cao, H., Wu, H., Qi, W., Tang, M., Yang, S., Liu, Y., & Qin, L. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.8559 · Cited by 12
“To date, rivaroxaban has been approved in numerous countries for the treatment and prevention of recurrent VTE; the drug demonstrates the same efficacy as warfarin, but poses a lower risk of bleeding, and is approved for the prevention of stroke in patients with nonvalvular atrial fibrillation (72), and for the preven…”
BackgroundWang, Y., Xu, X., & Wei, Z. (2024) · Journal of orthopaedic surgery · doi:10.1177/10225536241233473 · Cited by 14
A Systematic Review and Adjusted Indirect Comparison of Oral Anticoagulants
Cui, J., Wu, B., Liu, C., & Li, Z. (2014) · Orthopedics · doi:10.3928/01477447-20141023-07 · Cited by 11
Thromboembolism in Orthopedic Surgery
Llau, J. V. (2012) · Springer eBooks · doi:10.1007/978-1-4471-4336-9 · Cited by 10
Becattini, C., Pace, U., Rondelli, F., Delrio, P., Ceccarelli, G., Boncompagni, M., Graziosi, L., Visonà, A., Chiari, D., Avruscio, G., et al. (2019) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2019.11.015 · Cited by 11
Metadata
- Authors
- Eriksson, B. I., Borris, L. C., Friedman, R. J., Haas, S., Huisman, M. V., Kakkar, A. K., Bandel, T. J., Beckmann, H., Muehlhofer, E., Misselwitz, F., & Geerts, W.
- Affiliations
- Sahlgrenska University Hospital (SE)
- Aarhus University Hospital (DK)
- Medical University of South Carolina (US)
- Technical University of Munich (DE)
- Leiden University Medical Center (NL)
- Queen Mary University of London (GB)
- Bayer (Germany) (DE)
- University of Toronto (CA)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-06-26
- Volume
- 358
- Issue
- 26
- Pages
- 2765-2775
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2014491911
- Cited by
- 1,433
- References
- 25
- Citations by year
- 2026: 15 · 2025: 28 · 2024: 24 · 2023: 35 · 2022: 39 · 2021: 55 · 2020: 47 · 2019: 47 · 2018: 60 · 2017: 68 · 2016: 86 · 2015: 92 · 2014: 98 · 2013: 167 · 2012: 159
- FWCI
- 76.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- IrInSubria (University of Insubria) (submittedVersion, other-oa)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- rivaroxaban, enoxaparin, thromboprophylaxis, total hip arthroplasty, venous thromboembolism, deep vein thrombosis, pulmonary embolism, factor Xa inhibitors, major bleeding, postoperative anticoagulation
- MeSH terms
- Rivaroxaban, Adolescent, Adult, Aged, Aged, 80 and over, Anticoagulants, Double-Blind Method, Female, Humans, Male, Middle Aged, Morpholines, Pulmonary Embolism, Thiophenes, Enoxaparin, Arthroplasty, Replacement, Hip, Venous Thrombosis, Venous Thromboembolism, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.